JPH01502478A - 線維芽細胞のヒトβ１―インターフェロンの合成をコードする組換えプラスミドＤＮＡ ｐＰＲ―ＩＦＮβ１―１３、それの操作方法、および同プラスミドＤＮＡを含有する、ヒトβ１―インターフェロンを生産する大腸菌 - Google Patents
線維芽細胞のヒトβ１―インターフェロンの合成をコードする組換えプラスミドＤＮＡ ｐＰＲ―ＩＦＮβ１―１３、それの操作方法、および同プラスミドＤＮＡを含有する、ヒトβ１―インターフェロンを生産する大腸菌Info
- Publication number
- JPH01502478A JPH01502478A JP63502089A JP50208988A JPH01502478A JP H01502478 A JPH01502478 A JP H01502478A JP 63502089 A JP63502089 A JP 63502089A JP 50208988 A JP50208988 A JP 50208988A JP H01502478 A JPH01502478 A JP H01502478A
- Authority
- JP
- Japan
- Prior art keywords
- dna
- ifnβ1
- interferon
- plasmid
- ppr
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000013612 plasmid Substances 0.000 title claims description 102
- 241000588724 Escherichia coli Species 0.000 title claims description 41
- 102000003996 Interferon-beta Human genes 0.000 title claims description 33
- 108090000467 Interferon-beta Proteins 0.000 title claims description 33
- 238000000034 method Methods 0.000 title claims description 26
- 210000002950 fibroblast Anatomy 0.000 title claims description 23
- 230000015572 biosynthetic process Effects 0.000 title claims description 12
- 238000003786 synthesis reaction Methods 0.000 title claims description 11
- 108020004414 DNA Proteins 0.000 claims description 78
- 108090000623 proteins and genes Proteins 0.000 claims description 43
- 210000004027 cell Anatomy 0.000 claims description 31
- 239000012634 fragment Substances 0.000 claims description 25
- 108091008146 restriction endonucleases Proteins 0.000 claims description 25
- 108010050904 Interferons Proteins 0.000 claims description 22
- 102000014150 Interferons Human genes 0.000 claims description 21
- 229940079322 interferon Drugs 0.000 claims description 19
- 238000002360 preparation method Methods 0.000 claims description 18
- 229960000723 ampicillin Drugs 0.000 claims description 13
- 238000013518 transcription Methods 0.000 claims description 13
- 230000035897 transcription Effects 0.000 claims description 13
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 claims description 11
- 108020004705 Codon Proteins 0.000 claims description 9
- 101150054175 cro gene Proteins 0.000 claims description 9
- 102000012410 DNA Ligases Human genes 0.000 claims description 8
- 108010061982 DNA Ligases Proteins 0.000 claims description 8
- 230000000694 effects Effects 0.000 claims description 8
- 108090000790 Enzymes Proteins 0.000 claims description 7
- 239000011541 reaction mixture Substances 0.000 claims description 7
- 102000053602 DNA Human genes 0.000 claims description 6
- 108010042407 Endonucleases Proteins 0.000 claims description 6
- 102000004533 Endonucleases Human genes 0.000 claims description 6
- 102000004190 Enzymes Human genes 0.000 claims description 6
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims description 6
- 229940088710 antibiotic agent Drugs 0.000 claims description 6
- 238000012258 culturing Methods 0.000 claims description 6
- 229930182817 methionine Natural products 0.000 claims description 6
- 239000002773 nucleotide Substances 0.000 claims description 6
- 125000003729 nucleotide group Chemical group 0.000 claims description 6
- 108091026890 Coding region Proteins 0.000 claims description 5
- 102000004594 DNA Polymerase I Human genes 0.000 claims description 5
- 108010017826 DNA Polymerase I Proteins 0.000 claims description 5
- 241000701959 Escherichia virus Lambda Species 0.000 claims description 5
- 238000000855 fermentation Methods 0.000 claims description 4
- 230000004151 fermentation Effects 0.000 claims description 4
- 230000000977 initiatory effect Effects 0.000 claims description 4
- 108020004707 nucleic acids Proteins 0.000 claims description 4
- 102000039446 nucleic acids Human genes 0.000 claims description 4
- 150000007523 nucleic acids Chemical class 0.000 claims description 4
- 230000010076 replication Effects 0.000 claims description 4
- 238000011160 research Methods 0.000 claims description 4
- 239000003242 anti bacterial agent Substances 0.000 claims description 3
- 230000035800 maturation Effects 0.000 claims description 3
- 244000005700 microbiome Species 0.000 claims description 3
- 101000702488 Rattus norvegicus High affinity cationic amino acid transporter 1 Proteins 0.000 claims description 2
- 230000003247 decreasing effect Effects 0.000 claims description 2
- 239000001226 triphosphate Substances 0.000 claims description 2
- 235000011178 triphosphate Nutrition 0.000 claims description 2
- UNXRWKVEANCORM-UHFFFAOYSA-N triphosphoric acid Chemical compound OP(O)(=O)OP(O)(=O)OP(O)(O)=O UNXRWKVEANCORM-UHFFFAOYSA-N 0.000 claims description 2
- 101100298844 Parengyodontium album PROR gene Proteins 0.000 claims 1
- 108020004682 Single-Stranded DNA Proteins 0.000 claims 1
- 108020005038 Terminator Codon Proteins 0.000 claims 1
- 229930189851 creoside Natural products 0.000 claims 1
- 238000006116 polymerization reaction Methods 0.000 claims 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 30
- 239000002609 medium Substances 0.000 description 13
- 102000004169 proteins and genes Human genes 0.000 description 13
- 239000002244 precipitate Substances 0.000 description 12
- 239000000047 product Substances 0.000 description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- 239000000872 buffer Substances 0.000 description 7
- 239000000499 gel Substances 0.000 description 7
- 239000002502 liposome Substances 0.000 description 7
- 230000009466 transformation Effects 0.000 description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 5
- 229940047124 interferons Drugs 0.000 description 5
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 238000010561 standard procedure Methods 0.000 description 4
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 3
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 238000003776 cleavage reaction Methods 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 229920002401 polyacrylamide Polymers 0.000 description 3
- 230000006798 recombination Effects 0.000 description 3
- 238000005215 recombination Methods 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 230000007017 scission Effects 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 238000013519 translation Methods 0.000 description 3
- 230000014616 translation Effects 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- ZKHQWZAMYRWXGA-KQYNXXCUSA-J ATP(4-) Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-J 0.000 description 2
- ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 239000002028 Biomass Substances 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- XDFCIPNJCBUZJN-UHFFFAOYSA-N barium(2+) Chemical compound [Ba+2] XDFCIPNJCBUZJN-UHFFFAOYSA-N 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 229960005091 chloramphenicol Drugs 0.000 description 2
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 210000005260 human cell Anatomy 0.000 description 2
- 210000002429 large intestine Anatomy 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- 230000002906 microbiologic effect Effects 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 101150079601 recA gene Proteins 0.000 description 2
- 230000002103 transcriptional effect Effects 0.000 description 2
- PIEPQKCYPFFYMG-UHFFFAOYSA-N tris acetate Chemical compound CC(O)=O.OCC(N)(CO)CO PIEPQKCYPFFYMG-UHFFFAOYSA-N 0.000 description 2
- 241001515965 unidentified phage Species 0.000 description 2
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 240000003291 Armoracia rusticana Species 0.000 description 1
- 235000011330 Armoracia rusticana Nutrition 0.000 description 1
- 244000063299 Bacillus subtilis Species 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 241001000171 Chira Species 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 241000588921 Enterobacteriaceae Species 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000006992 Interferon-alpha Human genes 0.000 description 1
- 108010047761 Interferon-alpha Proteins 0.000 description 1
- 125000000174 L-prolyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])([H])[C@@]1([H])C(*)=O 0.000 description 1
- 108091071262 Lambda family Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 101100355584 Mus musculus Rad51 gene Proteins 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 239000001888 Peptone Substances 0.000 description 1
- 108010080698 Peptones Proteins 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 108010010677 Phosphodiesterase I Proteins 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- 108091006629 SLC13A2 Proteins 0.000 description 1
- 108091081024 Start codon Proteins 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- PTHYCBGWNSSYAV-UHFFFAOYSA-N acetic acid;2-[2-[bis(carboxymethyl)amino]ethyl-(carboxymethyl)amino]acetic acid Chemical compound CC(O)=O.OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O PTHYCBGWNSSYAV-UHFFFAOYSA-N 0.000 description 1
- 102000005421 acetyltransferase Human genes 0.000 description 1
- 108020002494 acetyltransferase Proteins 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 238000005273 aeration Methods 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Natural products N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 210000003969 blast cell Anatomy 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 230000010307 cell transformation Effects 0.000 description 1
- 230000000112 colonic effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 238000012136 culture method Methods 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000000120 cytopathologic effect Effects 0.000 description 1
- HAAZLUGHYHWQIW-KVQBGUIXSA-N dGTP Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 HAAZLUGHYHWQIW-KVQBGUIXSA-N 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 239000005549 deoxyribonucleoside Substances 0.000 description 1
- 230000003544 deproteinization Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000012407 engineering method Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000007071 enzymatic hydrolysis Effects 0.000 description 1
- 238000006047 enzymatic hydrolysis reaction Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 206010023332 keratitis Diseases 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- -1 mercaptoethyl adenosine triphosphate Chemical compound 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 238000013048 microbiological method Methods 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 230000009456 molecular mechanism Effects 0.000 description 1
- 150000004712 monophosphates Chemical class 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 229940126619 mouse monoclonal antibody Drugs 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 125000003835 nucleoside group Chemical group 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 235000019319 peptone Nutrition 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 229940057847 polyethylene glycol 600 Drugs 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000008844 regulatory mechanism Effects 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 230000002623 sporogenic effect Effects 0.000 description 1
- 208000003265 stomatitis Diseases 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000012134 supernatant fraction Substances 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000005026 transcription initiation Effects 0.000 description 1
- 239000012137 tryptone Substances 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
- C07K14/565—IFN-beta
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SU4191345/28 | 1987-02-09 | ||
| SU874191345A SU1703692A1 (ru) | 1987-02-09 | 1987-02-09 | Рекомбинантна плазмидна ДНК @ -1 @ 1-13, кодирующа синтез фибробластного интерферона ( @ I) человека, способ ее конструировани , штамм бактерий ЕSснеRIснIа coLI - продуцент @ I-интерферона человека |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JPH01502478A true JPH01502478A (ja) | 1989-08-31 |
Family
ID=21284355
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP63502089A Pending JPH01502478A (ja) | 1987-02-09 | 1988-02-08 | 線維芽細胞のヒトβ１―インターフェロンの合成をコードする組換えプラスミドＤＮＡ ｐＰＲ―ＩＦＮβ１―１３、それの操作方法、および同プラスミドＤＮＡを含有する、ヒトβ１―インターフェロンを生産する大腸菌 |
Country Status (9)
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2008523801A (ja) * | 2004-12-20 | 2008-07-10 | カディラ ヘルスケア リミティド | 高レベルのインターフェロンベータの調製方法 |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0593792B2 (en) * | 1992-10-14 | 2004-01-07 | Ajinomoto Co., Inc. | Novel L-threonine-producing microbacteria and a method for the production of L-threonine |
| RU2386694C2 (ru) * | 2006-05-05 | 2010-04-20 | ООО "Биотех" | Штамм дрожжей pichia pastoris - продуцент гамма-интерферона цыпленка, рекомбинантная плазмидная днк, обеспечивающая биосинтез гамма-интерферона цыпленка, и способ ее конструирования |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4582800A (en) * | 1982-07-12 | 1986-04-15 | Hoffmann-La Roche Inc. | Novel vectors and method for controlling interferon expression |
-
1987
- 1987-02-09 SU SU874191345A patent/SU1703692A1/ru active
-
1988
- 1988-02-08 CH CH3815/88A patent/CH676996A5/de not_active IP Right Cessation
- 1988-02-08 JP JP63502089A patent/JPH01502478A/ja active Pending
- 1988-02-08 NL NL8820103A patent/NL8820103A/nl unknown
- 1988-02-08 HU HU881692A patent/HUT50871A/hu unknown
- 1988-02-08 WO PCT/SU1988/000033 patent/WO1988005819A1/ru active Application Filing
- 1988-10-04 FI FI884556A patent/FI884556A0/fi not_active Application Discontinuation
- 1988-10-07 SE SE8803567A patent/SE8803567D0/xx not_active Application Discontinuation
- 1988-10-10 GB GB8823728A patent/GB2208866A/en not_active Withdrawn
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2008523801A (ja) * | 2004-12-20 | 2008-07-10 | カディラ ヘルスケア リミティド | 高レベルのインターフェロンベータの調製方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| CH676996A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | 1991-03-28 |
| WO1988005819A1 (fr) | 1988-08-11 |
| FI884556A7 (fi) | 1988-10-04 |
| GB2208866A (en) | 1989-04-19 |
| NL8820103A (nl) | 1989-01-02 |
| FI884556A0 (fi) | 1988-10-04 |
| GB8823728D0 (en) | 1988-12-07 |
| HUT50871A (en) | 1990-03-28 |
| SE8803567L (sv) | 1988-10-07 |
| SU1703692A1 (ru) | 1992-01-07 |
| SE8803567D0 (sv) | 1988-10-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI64813C (fi) | Foerfarande foer producering av ett utvalt aeggviteaemne och vid foerfarandet anvaenda rekombinantplasmidvektorer | |
| JP2687995B2 (ja) | Ｄｎａ配列、組替えｄｎａ分子およびヒト繊維芽細胞インターフェロン様ポリペプチドの製造方法 | |
| JPH0838177A (ja) | 組換ｄｎａ分子の作製方法 | |
| JPS63159397A (ja) | 組換えｂ型肝炎ウィルス抗原 | |
| CN115806926B (zh) | 一种生产假尿苷的基因工程菌株及其构建方法与应用 | |
| JPH0665305B2 (ja) | 組換えｄｎａ含有宿主細胞の安定化法 | |
| JPS6214786A (ja) | グラム陽性菌の新規発現調節配列 | |
| CN113957071B (zh) | 一种具有双重启动子和双重分泌信号功能的组合dna片段及其应用 | |
| CN111117942A (zh) | 一种产林可霉素的基因工程菌及其构建方法和应用 | |
| JPH01502478A (ja) | 線維芽細胞のヒトβ１―インターフェロンの合成をコードする組換えプラスミドＤＮＡ ｐＰＲ―ＩＦＮβ１―１３、それの操作方法、および同プラスミドＤＮＡを含有する、ヒトβ１―インターフェロンを生産する大腸菌 | |
| EP0133321A1 (en) | DNA gene, process for production thereof and plasmid containing the same | |
| SU1479005A3 (ru) | Способ получени интерлейкина-2 человека | |
| EP0048497A2 (en) | DNA transducing vector and microorganism containing it | |
| EP0183571A2 (en) | Cosmid vectors | |
| US4585739A (en) | Plasmid for foreign gene expression in B. subtilis | |
| CA1275954C (en) | 3'-expression enhancing fragments and method | |
| RU2045575C1 (ru) | Рекомбинатная плазмидная днк ppr - tgatg - hil - 1 beta - tsr, обеспечивающая синтез рекомбинантного интерлейкина-1 и штамм escherichia coli - продуцент рекомбинантного интерлейкина-1 бета человека | |
| RU2180003C2 (ru) | Рекомбинантная плазмидная днк, обеспечивающая синтез фибробластного интерферона человека клетками дрожжей, способ ее конструирования и штамм дрожжей saccharomyces cerevisiae-продуцент фибробластного интерферона человека | |
| JPS61502799A (ja) | 組換えｄｎａ分子、形質転換された微生物、並びにペニシリンｖアミダ−ゼの製造方法 | |
| CN107383207A (zh) | 一种重组犬长效干扰素α及制备此长效干扰素的融合蛋白及其制备方法 | |
| EP0314184A1 (en) | Expression plasmids | |
| JPH01502639A (ja) | ヒトインターロイキン―２の合成についてコードする組換えプラスミドＤＮＡｐＰＲ―１Ｌ２―１９、その工学的作出方法及びそれを含有するヒトインターロイキン―２産生細菌大腸菌ＶＮ２ジェネティカＶＬ９０３（ｐＰＲ―１Ｌ２―１９）株 | |
| JPS5965099A (ja) | 発現用プロモ−タ−およびその用途 | |
| KR890002417B1 (ko) | 대장균에 인간의 면역 인터페론(Hu-IFN-γ) 생산특성을 부여하는 플라스미드 pKB-1000-γ의 제조방법 | |
| EP0355625B1 (en) | Gene regulation cassettes, exüressopm vectors containing the same and microorganisms transformed with the same |